Duke University Health SystemDr. Victor J. Dzau, the current president and CEO of Duke University Health System Dr. Victor J. Dzau, the current president and CEO of Duke University Health System and chancellor for health affairs at Duke University, has been appointed to a six-year term as the next president of the Institute of Medicine (IOM), effective July 1, 2014. Dr. Dzau will take over the lead role from Dr. Harvey Fineberg, who served in the position for twelve years. Dr. Dzau began his career in medicine as a cardiologist, having previously taught at Harvard Medical School and served as chair of the department of medicine. He also worked at Brigham and Womens Hospital as the director of research. His ongoing award-winning research has been key in the development of cardiovascular drugs, as well as techniques to repair tissue damage from heart attacks and heart disease using stem cell therapies. Dr. Eugene Braunwald, often called the father of modern cardiology and a professor of medicine at Harvard Medical School, has known Dr. Dzau for more than 40 years and worked with him at many different stages of his career at Brigham and Womens Hospital and Partners Healthcare. In an interview … Continue reading →

Laminine Testimonial - Chronic Kidney Disease Laminine is availabe in the Philippines!!! "The Closest Alternative To Stem Cell Therapy..." "The miracle formula from a 9-day-old fertilized hen eggs" For M... By: Julfran Ytang … Continue reading →

Stem Cell Treatment at "EmCell" http://www.emcell.com/ Stem cell therapy is the rapidly developing area of modern medicine. Unique properties of fetal stem cells, the core of EmCell treatme... By: Stem Cell Therapy Center "EMCELL" … Continue reading →

CardioCell has begun two new clinical trials of its stem cell treatment for recent heart attack patients, the San Diego company said Wednesday. A Phase 3 trial has started in Kazakhstan and a Phase 2a trial in the United States, said privately held CardioCell. The stem cells are grown under low oxygen conditions, similar to the natural environment of stem cells in the body, said cardiologist Stephen Epstein, a scientific advisor. Stem cells grown under higher levels of oxygen common in laboratory environments act differently than those grown in low oxygen levels, which may reduce their regenerative abilities, said Epstein, director of translational and vascular biology research at MedStar Heart Institute in Washington, D.C. Moreover, these cells tolerate ischemia, a reduced blood supply that limits the availability of oxygen and nutrients. Since heart attacks are by definition caused by ischemia, that tolerance should help the cells survive long enough to help, Epstein said. The stem cells appear to help by producing chemicals that stimulate heart regeneration, Epstein said. The stem cells are of a type called mesenchymal, taken from bone marrow. They were produced by Stemedica, another San Diego stem cell company, which spun off CardioCell. More information about the … Continue reading →

By Marcus Johnson Bumetanide is a drug approved for the treatment of heart and liver disease. It is now being repurposed to treat autism and researchers are in the first stages of studying the drug. Researchers would like to know if bumetanide can stop or reverse autism in children and theyve started by testing the drug on animals such as mice and rats. Researchers found that bumetanide reversed a faulty birth mechanism that may have led to autism symptoms in offspring. The next step for researchers is to test bumetanide on children. Researchers who have worked on the studies are optimistic. If you administer a diuretic to the mother 24 hours before delivery, the offspring is, so to speak, cured, said Yehezkel Ben-Ari, the study author. What we must do is work in the development and biology earlier so we see, this is insufficient and how we can treat it earlier. While the studys results are positive, it is not yet determined if the drugs effects on animals will be similar in humans. G. Ian Gallicano, a biologist at Georgetown, is skeptical. I think 90 percent of this paper is really earth-shattering, but there's always the caution of, 'is this … Continue reading →

PUBLIC RELEASE DATE: 19-Feb-2014 Contact: Jim Ritter jritter@lumc.edu 708-216-2445 Loyola University Health System MAYWOOD, IL A major study has found that giving stroke patients medications to lower their blood pressure during the first 48 hours after a stroke does not reduce the likelihood of death or major disability. The study is published in the Journal of the American Medical Association. At least 25 percent of the population has high blood pressure, which greatly increases the risk of stroke. Lowering blood pressure has been shown to reduce the risk of stroke. The study investigated whether there also would be a benefit to lowering blood pressure immediately after a stroke. The study included more than 4,000 stroke patients in 26 hospitals across China, who were randomly assigned to receive blood pressure medications or to discontinue blood pressure medications. At 14 days or hospital discharge, there were no statistically significant differences between the groups in mortality or disability. Blood pressure often is elevated following a stroke. "But in most cases, treatment is unnecessary because the blood pressure declines naturally over time, and lowering blood pressure may be contraindicated," said stroke specialist Jose Biller, MD, chair of the Department of Neurology of Loyola University … Continue reading →